

Patient Reported Outcomes for Multiple Sclerosis

The impact of PROMs in developing emerging therapies

12 November 2025 (8:30–13:00 CET)

Agenda

Welcome Session and Introduction

Time	Duration	Session Title	Speakers	
8:30-8:45	15'	Welcome	Lydia Makaroff Xavier Montalban	MS International Federation Centro de Esclerosis Múltiple de Cataluña (Cemcat)
			Hans-Peter Hartung	Heinrich-Heine University Düsseldorf
		Lived experience perspective The urgent need for relevant PROMs to improve therapy development and access	Helga Weiland PROMS ECT Co-Chair	

Welcome Session and Introduction

Time	Duration	Session Title	Speakers	
8:45-8:55	10'	Meeting agenda and aims Overview of meeting objectives	Paola Zaratin Patrick Vermersch	Italian MS Society Université de Lille
		Context: the path forward to increase the uptake of PROMs in clinical research in the context of new clinical descriptors without undermining the rigor of EMA PROMs validation and use in decision-making.		

Session 1: EMA Reflection Paper on Patient Experience Data in Q2-3 2025

Moderators: Elena H. Martínez-Lapiscina [European Medicines Agency](#) Mario Alberto Battaglia [Italian MS Society](#)

Time	Duration	Session Title	Speakers
8:55–9:15	20'	Keynote Speech: The Value of Patient Experience Data (PED) in Medicines Development and Regulation: An EU Perspective	Juan Garcia Burgos European Medicines Agency
9:15–9:25	10'	ECT response to the EMA reflection paper	Meenakshi Nandakumar PROMS ECT
9:25–9:45	20'	Discussion Implications of reflection paper for PROMs in MS; When and how to engage EMA (e.g., Innovation Task Force); Differences in evidence standards for various regulatory goals.	
9:45–10:00	15'	Coffee break	

Session 2: **Clinical descriptors and new classification - Bridging biological disease mechanisms with different clinical states: the role of PROMs in phenotyping MS**

Moderators: Patrick Vermersch [Université de Lille](#) Maria Pia Amato [Università di Firenze](#)

Time	Duration	Session Title	Speakers
10:00-10:10	10'	Lived experience perspective on MS classification	Marilena Hadjiyianni PROMS ECT
10:10-10:25	15'	Redefining MS disease descriptors and phenotypes	Alan Thompson University College London
10:25-10:40	15'	New clinical descriptors rooted on PROMs: myth or reality	Giampaolo Brichetto Italian MS Society
10:40-10:55	15'	Redefining Rating Scale Data Analysis in MS Trials: Report from the PROMS Workshop	Jeremy Charles Hobart University of Plymouth
10:55-11:15	20'	Discussion Role of PROMs in capturing progression beyond relapses; The case for phase-specific and phenotype-specific PROMs; Aligning biological and experiential data; PROMs standardisation has to happen together with their personalized use.	
11:15-11:30	15'	Coffee break	

Session 3: **Alignment of stakeholders for PROs for emerging therapies**

Moderators: Xavier Montalban [Centro de Esclerosis Múltiple de Cataluña \(Cemcat\)](#) Nektaria Alexandri [Merck](#)

11:30-11:45	15'	Successful PROs development from rare neurological diseases: the case of Myasthenia Gravis (MG)	Carlo Antozzi Istituto Neurologico Carlo Besta
11:45-12:00	15'	Industry perspective on integration of PROs to drug development	Tammy McIver Roche
12:00-12:15	15'	Regulatory perspective on alignment of PROs and drug development	Elena H. Martínez-Lapiscina European Medicines Agency

Session 4: **Potential roadmap and next steps**

Moderators: Lydia Makaroff [MS International Federation](#)

12:15-12:25	10'	Lived experience perspective: call to action	R van den Bos PROMS ECT
12:25-12:55	30'	Discussion panel Moderator: Daniel Ontaneda Cleveland Clinic	Panel Members: Carmen Tur Jeremy C. Hobart Patrick Vermersch Agné Kazlauskaitė Elena H. M.-Lapiscina Alan Thompson Paola Zaratin ECT member Centro de Esclerosis Múltiple de Cataluña University of Plymouth Université de Lille Roche EMA University College London Italian MS Society

Session 5: **Closure**

Time	Duration	Session Title	Speakers
12:55-13:00	5'	Closing remarks	Hans-Peter Hartung Heinrich-Heine University Düsseldorf